HUTCHMED

We are pleased to share that our partner Takeda has received positive CHMP Opinion for a new treatment for adults with previously treated metastatic #ColorectalCancer #mCRC throughout the European Union, Norway, Liechtenstein and Iceland. Learn More:https://lnkd.in/gnwjpgCR

New and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research Annual Meeting 2024 #AACR24 , taking place on April 5-10, 2024 in San Diego, California. https://lnkd.in/gMNzSavN

We are happy to share that, in collaboration with Innovent Biologics, the New Drug Application (NDA) for the combination of fruquintinib and sintilimab for the treatment of patients with advanced endometrial cancer has been accepted and granted priority review by the China National Medical Products Administration. https://lnkd.in/ghYRFhFr

The supplemental New Drug Application (sNDA) for savolitinib, in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alteration, has been accepted for review by the China National Medical Products Administration. If approved, the new label indication for savolitinib will be expanded to include treatment-naive patients in China. https://lnkd.in/guMVw_nH

We are pleased to announce that we have initiated the registration stage of the Phase II/III clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) in China. wAIHA is an autoimmune disorder that can lead to anemia and has limited treatment options. This follows positive data from the proof-of-concept Phase II stage of the trial and subsequent consultation with the China National Medical Products Administration. If positive, the data from the trial may be used to support a future New Drug Application filing. https://lnkd.in/g2NfJt-k

2023 was an important year for HUTCHMED. We made significant progress and executed against our commitment to bring our innovative medicines to patients worldwide, while remaining dedicated to becoming a self-sustaining business. Today, we are happy to report our 2023 Full Year Financial Results: https://lnkd.in/deweff_c

We will be announcing our 2023 final results on Wednesday, February 28, 2024. Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. https://lnkd.in/gbTek2a7

Data from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric cancer in China, were presented at the American Society of Clinical Oncology (ASCO) Plenary Series Session on February 6, 2024. Follow the link for the full presentation: https://lnkd.in/gjPwBwTN